The global COVID-19 vaccine surplus: tackling expiring stockpiles
BMC (March 20th, 2023) – (Opinion) A global surplus of coronavirus disease 2019 (COVID-19) vaccines exists as a result of difficulties in aligning the demand and supply for vaccine manufacturing and delivery. World leaders have accelerated vaccine development, approval, production and distribution as a pragmatic approach to addressing the immediate public health challenges of the first two and a half years of the pandemic.
https://idpjournal.biomedcentral.com/articles/10.1186/s40249-023-01070-7